CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC

Bookmark and Share
Published: 16 Apr 2021
Views: 2119
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Dr Luis Paz-Ares speaks to ecancer about the CheckMate 9LA study. It investigates the first-line nivolumab ipilimumab 2 cycles chemotherapy vs 4 cycles chemo in aNSCLC.

Initially, he explains the rationale of his study. In this study, the efficacy of nivolumab ipilimumab and chemotherapy was evaluated by tissue and blood TMB (tTMB/bTMB).

He then talks about the methodology of his study. Dr Paz-Ares further discusses the results of his study. He says that higher TMB appeared to be associated with improved PFS and ORR benefits of NIVO IPI chemo over chemo.

OS benefit was generally similar between high and low TMB. In the end, he discusses the future impact of this study on the treatment of NSCLC.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.